| Literature DB >> 21234253 |
Razieh Mohammadjafari1, Parvin Abedi, Syfolah Belady, Tarlan Hamidehkho, Taghi Razi.
Abstract
The present case study is on a 16-year-old woman who was suffering from nephrotic syndrome after recovery from complete type of hydatiform mole. She was admitted in hospital because of proteinurea and hematuria. Then she was showing a generalized edema compatible with neprhotic syndrome. In her past medical history she had a suction curettage for hydatiform mole. After she received 4 courses chemotherapy, she completely recovered and βhCG has fallen from 12127 IU/L to under 10 IU/mL. Then she showed generalized edema, proteinurea and hematuria compatible with nephritic syndrome. After six courses chemotherapy the symptoms of nephrotic syndrome and invasive mole diminished, she released from hospital and scheduled for follow-up.Entities:
Keywords: chemotherapy.; hydatiform mole; nephrotic syndrome
Year: 2010 PMID: 21234253 PMCID: PMC3019596 DOI: 10.4081/rt.2010.e61
Source DB: PubMed Journal: Rare Tumors ISSN: 2036-3605
Figure 1Photomicrograph of complete mole; multiple large villi show stromal edema and marked trophoblastic proliferation.
Paraclinical tests in the patient suspected to the nephritic syndrome
| Tests | Results |
|---|---|
| Urinalysis | |
| Proteinuria | 4+ |
| Red blood cell in high power fields | 10–12 |
| Hemoglobin | 1+ |
| WBC in high power field | 8–10 |
| 24 urinary protein exertion | 9400 mg |
| Liver function tests | |
| SGOT | 24 µg/L |
| SGPT | 22 µg/L |
| Bilirubin | 0.8 mg/dL |
| Partial thromboplastin time | 30 sec |
| Prothrombin activity | 81% |
| Total blood count test | |
| Hemoglobin | 13 g/dL |
| WBC ×1000/mm3 | 11.6 |
| Platelets ×1000/mm3 | 270 |
| Blood urea nitrogen | 7 mg/dL |
| Creatinin | 0.7 mg/dL |
| Sodium | 139 µg/L |
| Potassium | 4.2 µmg/L |
| Calcium | 8/9 mg/dL |
| Phosphorous | 4.6 mg/dL |
Paraclinical tests in the patient suspected to the nephrotic syndrome.
| Blood tests for lipid and antibodies | Results |
|---|---|
| Total cholesterol | 322 mg/dL |
| Triglycerids | 393 mg/dL |
| High density lipoprotein | 33 mg/dL |
| Low density lipoprotein | 270 mg/dL |
| Very low density lipoprotein | 18 mg/dL |
| International ratio | 1.1 |
| Erythrocyte sedimentation rate | 52 mm/hr |
| C-reactive protein | 3+ |
| Complement component 3 | 150 mg/dL (86–184 mg/dL) |
| Complement component | 20.3 mg/dL (20–57 mg/dL) |
| The dose of complement that lyses 50% of a red cell suspension | 94 U/mL (63–184 U/mL) |
| Glomerular basement membrane | Negative |
| Antinuclear antibody test | 1/40 |
| Protoplasmic-staining antineutrophil cytoplasmic antibodie | <1.4 U mL |
| Classical antineutrophil cytoplasmic antibodies | Negative (normal <2.8 U/mL) |
| Antids-DNA | 1/10 |
| Antiphospholipid (immunoglobulin G antibodies) | 5.1 mg/dL |
| Immuunoglobolin M antibodies | 3 mg/dL (0–15 mpl) |
Reduction of βhCG after chemotherapy
| Weeks of treatment | βhCG (U/mL) |
|---|---|
| In time of diagnosis of nephrotic syndrome | 12127 |
| 1st week after chemotherapy | 17124 |
| 2nd week after chemotherapy | 4370 |
| 3rd week after chemotherapy | 687 |
| 4th week after chemotherapy | 67 |
| 5th week after chemotherapy | <10 |
| 6th week after chemotherapy | <10 |